• 2016

      Qinxue Wang1, Haobin Huang2...

      Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC).

      Ver PDF (829 kb)
    • 2012

      Daniel E. Gomez

      Cancer antigen prioritization: a road map to work in defining vaccines against specific targets.

      Ver PDF (217 kb)
    • 2012

      Roberto E. Gomez

      Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective.

      Ver PDF (922 kb)
    • 2003

      Luis E Fernández

      Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer.

      Ver PDF (241 kb)
    • 2002


      In Vivo and In Vitro Anti-Tumor Effect of 14F7 Monoclonal Antibody.

      Ver DOC (150 kb)
    • 2001


      Immunogenetic Analysis of Variable Regions Encoding AB1 and g-Type AB2 Antibodies from the NeuGc-Containing Ganglioside Family.

      Ver PDF (322 kb)

    • 2007

      C. Venier

      Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant.

      Ver PDF (367 kb)
    • 2006

      Mariano R. Gabri

      Complete Antitumor Protection by Perioperative Immunization with GM3/VSSP Vaccine in a Preclinical Mouse Melanoma Model.

      Ver DOC (417 kb)
    • 2004

      Marcelo D. Guthmann

      Active Specific Immunotherapy of Melanoma with a GM3 Ganglioside-Based Vaccine.

      Ver PDF (3528 kb)
    • 2004

      Circe Mesa

      Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction...

      Ver PDF (296 kb)
    • 2002

      Mariano R. Gabri

      Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.

      Ver PDF (603 kb)

    • 2001

      A. Carr

      A puri®ed GM3 ganglioside conjugated vaccine induces speci®c, adjuvant-dependent and non- transient antitumour activity...

      Ver PDF (265 kb)
    • 2000

      Francisco Estevez

      Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size...

      Ver DOC (175 kb)
    • 1999

      daniel f. alfonso

      A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor...

      Ver PDF (3150 kb)

    • 2010

      Immunogenicity and safety in breast cancer patients (phase II trial).

      Ver PDF (837 kb)
    • 2003

      Adriana Carr

      Immunotherapy of Advanced Breast Cancer With a Heterophilic Ganglioside (NeuGcGM3) Cancer Vaccine.

      Ver PDF (182 kb)

    • 2014

      Saily Alfonso

      Randomized, Multicenter, Placebo-controlled Clinical Trial of Racotumomab-Alum Vaccine...

      Ver PDF (768 kb)
    • 2014

      Amparo Macías

      Combination of Platinum standard first front line chemotherapy and Vaxira vaccine...

      Ver DOC (501 kb)
    • 2014

      Z. Gajdosik

      Racotumomab a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.

      Ver PDF (106 kb)
    • 2014

      Hanice M. Reichert

      Antibodies to watch 2014.

      Ver PDF (183 kb)
    • 2014

      Ron Amon

      Glycans in immune recognition and response.

      Ver PDF (913 kb)

    • 2014

      Eduardo Santiesteban

      Racotumomab as 2nd Line.

      Ver PDF (966 kb)
    • 2013

      Daniel E. Gomez

      Anti-idiotype antibodies in cancer treatment.

      Ver PDF (278 kb)
    • 2012

      Valeria I. Segator

      Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl...

      Ver DOC (753 kb)
    • 2012

      Ana M. Vázquez

      Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides – preclinical and clinical data.

      Ver PDF (232 kb)
    • 2012

      Ana M. Vázquez

      Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry.

      Ver PDF (1764 kb)

    • 2012

      Macías A.

      Active specific immunotherapy with racotumomab in the treatment of advanced non small cell lung cancer (NSCLC).

      Ver PDF (1359 kb)
    • 2012

      Macías A.

      Racotumomab administration in patients with advanced non-small-cell lung cancer (NSCLC)...

      Ver PDF (8902 kb)
    • 2011

      Ana María Hernández

      Funciones efectoras de los anticuerpos anti-NeuGC-GM3 inducidos por racotumomab.

      Ver PDF (1642 kb)
    • 2010


      Expresión de N-glicolil GM3 en tumores pediátricos candidatos a inmunoterapia con racotumomab.

      Ver DOC (1837 kb)
    • 2009

      Ariel Talavera

      Capacidad de racotumomab de inducir anticuerpos anti-gangliósido: hipótesis derivadas del modelaje.

      Ver PDF (1217 kb)

    • 2008

      Ana María Herna´ndez

      Caracterización de la respuesta de Ac anti-NeuGcGM3 en cáncer de pulmón de células no pequeñas.

      Ver PDF (720 kb)
    • 2007

      saily Alfonso1

      Seguridad e inmunogenicidad en pacientes con cáncer de pulmón de células no pequeñas (NSCLC).

      Ver PDF (552 kb)
    • 2007

      Elia Neninger

      Seguridad e inmunogenicidad en pacientes con cáncer de pulmón de células pequeñas (SCLC).

      Ver PDF (1282 kb)
    • 2006

      Marcelo D. Guthmann

      Seguridad e inmunogenicidad en pacientes con cáncer de mama.

      Ver DOC (172 kb)
    • 2003

      Alain Díaz

      Respuesta inmune en pacientes con cáncer de mama.

      Ver PDF (368 kb)